Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab

This case series describes the outcomes of COVID-19 and SARS-CoV-2 vaccination in patients with atopic dermatitis who have been treated with tralokinumab.

Detalles Bibliográficos
Autores principales: Blauvelt, Andrew, Pink, Andrew, Worm, Margitta, Langley, Richard G. B., Elewski, Boni E., Gjerum, Le, Guttman-Yassky, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558055/
https://www.ncbi.nlm.nih.gov/pubmed/36223087
http://dx.doi.org/10.1001/jamadermatol.2022.3488
_version_ 1784807365455904768
author Blauvelt, Andrew
Pink, Andrew
Worm, Margitta
Langley, Richard G. B.
Elewski, Boni E.
Gjerum, Le
Guttman-Yassky, Emma
author_facet Blauvelt, Andrew
Pink, Andrew
Worm, Margitta
Langley, Richard G. B.
Elewski, Boni E.
Gjerum, Le
Guttman-Yassky, Emma
author_sort Blauvelt, Andrew
collection PubMed
description This case series describes the outcomes of COVID-19 and SARS-CoV-2 vaccination in patients with atopic dermatitis who have been treated with tralokinumab.
format Online
Article
Text
id pubmed-9558055
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-95580552022-10-28 Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab Blauvelt, Andrew Pink, Andrew Worm, Margitta Langley, Richard G. B. Elewski, Boni E. Gjerum, Le Guttman-Yassky, Emma JAMA Dermatol Research Letter This case series describes the outcomes of COVID-19 and SARS-CoV-2 vaccination in patients with atopic dermatitis who have been treated with tralokinumab. American Medical Association 2022-10-12 2022-11 /pmc/articles/PMC9558055/ /pubmed/36223087 http://dx.doi.org/10.1001/jamadermatol.2022.3488 Text en Copyright 2022 Blauvelt A et al. JAMA Dermatology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License.
spellingShingle Research Letter
Blauvelt, Andrew
Pink, Andrew
Worm, Margitta
Langley, Richard G. B.
Elewski, Boni E.
Gjerum, Le
Guttman-Yassky, Emma
Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
title Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
title_full Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
title_fullStr Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
title_full_unstemmed Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
title_short Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
title_sort outcomes of covid-19 and vaccination in patients with moderate to severe atopic dermatitis treated with tralokinumab
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558055/
https://www.ncbi.nlm.nih.gov/pubmed/36223087
http://dx.doi.org/10.1001/jamadermatol.2022.3488
work_keys_str_mv AT blauveltandrew outcomesofcovid19andvaccinationinpatientswithmoderatetosevereatopicdermatitistreatedwithtralokinumab
AT pinkandrew outcomesofcovid19andvaccinationinpatientswithmoderatetosevereatopicdermatitistreatedwithtralokinumab
AT wormmargitta outcomesofcovid19andvaccinationinpatientswithmoderatetosevereatopicdermatitistreatedwithtralokinumab
AT langleyrichardgb outcomesofcovid19andvaccinationinpatientswithmoderatetosevereatopicdermatitistreatedwithtralokinumab
AT elewskibonie outcomesofcovid19andvaccinationinpatientswithmoderatetosevereatopicdermatitistreatedwithtralokinumab
AT gjerumle outcomesofcovid19andvaccinationinpatientswithmoderatetosevereatopicdermatitistreatedwithtralokinumab
AT guttmanyasskyemma outcomesofcovid19andvaccinationinpatientswithmoderatetosevereatopicdermatitistreatedwithtralokinumab

Ejemplares similares